Amicus Therapeutics Q1 2021 Earnings Report
Key Takeaways
Amicus Therapeutics announced its Q1 2021 financial results, with a focus on the commercial growth of Galafold, the regulatory advancements for AT-GAA, and the progress of its gene therapy pipeline. The company is confident in meeting its full-year 2021 revenue guidance.
Galafold revenue reached $66.4M, driven by global growth.
The company held a positive pre-BLA meeting with the U.S. FDA for AT-GAA in Pompe disease, with a rolling BLA submission on track for completion in Q2 2021.
New data from Pompe and Fabry gene therapy programs will be presented at the American Society of Gene & Cell Therapy 24th Annual Meeting.
Sébastien Martel joined as SVP, Strategy & Business Development, strengthening the senior management team.
Amicus Therapeutics
Amicus Therapeutics
Amicus Therapeutics Revenue by Segment
Forward Guidance
Amicus Therapeutics is on-track to achieve revenue guidance of $300M-$315M.